Why Pancreatic Cancer Is So Aggressive: Biology & Barriers to Treatment

Pancreatic ductal adenocarcinoma (PDAC) has the worst 5-year survival (~12%) among major cancers due to convergent aggressive biology.

Key Aggressive Features

• Early metastasis: Disseminates before primary tumor detectable (circulating tumor cells in pre-malignant lesions).
• Desmoplastic stroma: Dense fibrotic matrix (cancer-associated fibroblasts, hyaluronan) → high interstitial pressure → poor drug delivery, immune exclusion.
• Immunologically "cold": Low T-cell infiltration, immunosuppressive TME (Tregs, MDSCs, M2 macrophages).
• Genomic instability: KRAS (90%), TP53 (75%), CDKN2A (90%), SMAD4 (55%) – few actionable targets.
• Metabolic reprogramming: Autophagy, macropinocytosis, stromal nutrient scavenging.
• Therapy resistance: Intrinsic (stromal barrier, cancer stem cells) + acquired.

Clinical Consequences

• 80–85% present with unresectable disease.
• Adjuvant chemo (mFOLFIRINOX/gemcitabine-capecitabine) improves cure rate for resected.
• Metastatic: FOLFIRINOX or gem/nab-paclitaxel extend survival modestly (median 11–13 mo).

Emerging Strategies

• Stroma-targeting (PEGPH20 failed; FAK inhibitors, CXCR4 in trials)
• Immunotherapy combinations (checkpoint + vaccine + stromal modulation)
• KRAS G12C inhibitors (adagrasib/sotorasib – rare in PDAC)
• Early detection: liquid biopsy, imaging surveillance in high-risk (hereditary, cysts).